{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:36:08Z","timestamp":1791549368839,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"crossref","award":["U01AA026980-07"],"award-info":[{"award-number":["U01AA026980-07"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12072-026-11096-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:06:10Z","timestamp":1779203170000},"page":"1020-1034","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease"],"prefix":"10.1007","volume":"20","author":[{"given":"Chencheng","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Elfeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-3998","authenticated-orcid":false,"given":"Ashwani K.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"4","key":"11096_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/hep.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u20131347. https:\/\/doi.org\/10.1097\/hep.0000000000000004","journal-title":"Hepatology"},{"issue":"6","key":"11096_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u20131986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"issue":"5","key":"11096_CR3","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000828","volume":"16","author":"N Dunn","year":"2025","unstructured":"Dunn N, Al-Khouri N, Abdellatif I, Singal AK. Metabolic dysfunction and alcohol-associated liver disease: a narrative review. Clin Transl Gastroenterol. 2025;16(5): e00828. https:\/\/doi.org\/10.14309\/ctg.0000000000000828","journal-title":"Clin Transl Gastroenterol"},{"issue":"10464","key":"11096_CR4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/s0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404(10464):1761\u20131778. https:\/\/doi.org\/10.1016\/s0140-6736(24)01811-7","journal-title":"Lancet"},{"issue":"13","key":"11096_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.cgh.2025.02.007","volume":"23","author":"M Israelsen","year":"2025","unstructured":"Israelsen M, Thorhauge KH, Andersen P, Johansen S, Schnefeld HL, Bech KT, et al. Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments. Clin Gastroenterol Hepatol. 2025;23(13):2509\u20132518. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"11096_CR6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","volume":"83","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione F, D\u00edaz LA, Ajmera V, Madamba E, Singh S, Bettencourt R, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol. 2025;83(5):1023\u20131034. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.030","journal-title":"J Hepatol"},{"issue":"4","key":"11096_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab JP, Diaz LA, Rehm J, Im G, Arrese M, Kamath PS, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82(4):744\u2013756. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.028","journal-title":"J Hepatol"},{"issue":"17","key":"11096_CR8","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u20131569. https:\/\/doi.org\/10.1056\/NEJMoa2029349","journal-title":"N Engl J Med"},{"issue":"6","key":"11096_CR9","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cpt.3606","volume":"117","author":"Y Wu","year":"2025","unstructured":"Wu Y, Dong P, Wu Q, Zhang Y, Xu G, Pan C, et al. Insights into clinical trials for drugs targeting MASLD: progress, challenges, and future directions. Clin Pharmacol Ther. 2025;117(6):1614\u20131626. https:\/\/doi.org\/10.1002\/cpt.3606","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"11096_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cld.2024.06.017","volume":"28","author":"AV Kulkarni","year":"2024","unstructured":"Kulkarni AV, Singal AK, Kamath PS. Research priorities and future landscape of clinical trials in alcohol-associated liver disease. Clin Liver Dis. 2024;28(4):831\u2013851. https:\/\/doi.org\/10.1016\/j.cld.2024.06.017","journal-title":"Clin Liver Dis"},{"issue":"12","key":"11096_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41575-025-01120-5","volume":"22","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Thiele M, Louvet A, Lee BP, Ajmera V, Tavaglione F, et al. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. Nat Rev Gastroenterol Hepatol. 2025;22(12):866\u2013884. https:\/\/doi.org\/10.1038\/s41575-025-01120-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"11096_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001509","author":"FA Anania","year":"2025","unstructured":"Anania FA, Hager R, Higgins K, Makar GA, Siegel J, Tran TT. Non-invasive tests: establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-current perspectives from the division of hepatology and nutrition, US Food And Drug Administration. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001509","journal-title":"Hepatology"},{"issue":"11","key":"11096_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101569","volume":"7","author":"S Johansen","year":"2025","unstructured":"Johansen S, Thiele M, Krag A. Non-invasive tests for MetALD and alcohol-related liver disease. JHEP Rep. 2025;7(11): 101569. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101569","journal-title":"JHEP Rep"},{"issue":"2","key":"11096_CR14","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763\u2013772. https:\/\/doi.org\/10.1002\/hep.29797","journal-title":"Hepatology"},{"issue":"3","key":"11096_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1053\/j.gastro.2017.06.005","volume":"153","author":"MS Middleton","year":"2017","unstructured":"Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology. 2017;153(3):753\u2013761. https:\/\/doi.org\/10.1053\/j.gastro.2017.06.005","journal-title":"Gastroenterology"},{"issue":"2","key":"11096_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1148\/radiol.13121193","volume":"268","author":"D Kim","year":"2013","unstructured":"Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology. 2013;268(2):411\u2013419. https:\/\/doi.org\/10.1148\/radiol.13121193","journal-title":"Radiology"},{"issue":"3","key":"11096_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79(3):592\u2013604. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.025","journal-title":"J Hepatol"},{"issue":"1","key":"11096_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1148\/radiol.2017161398","volume":"285","author":"SD Serai","year":"2017","unstructured":"Serai SD, Obuchowski NA, Venkatesh SK, Sirlin CB, Miller FH, Ashton E, et al. Repeatability of MR elastography of liver: a meta-analysis. Radiology. 2017;285(1):92\u2013100. https:\/\/doi.org\/10.1148\/radiol.2017161398","journal-title":"Radiology"},{"issue":"2","key":"11096_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Arab JP, Idalsoaga F, Perelli J, Vega J, Dirchwolf M, et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann Hepatol. 2025;30(2): 101903. https:\/\/doi.org\/10.1016\/j.aohep.2025.101903","journal-title":"Ann Hepatol"},{"issue":"5","key":"11096_CR20","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u201381.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"issue":"2","key":"11096_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jhep.2018.11.025","volume":"70","author":"C Moreno","year":"2019","unstructured":"Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70(2):273\u2013283. https:\/\/doi.org\/10.1016\/j.jhep.2018.11.025","journal-title":"J Hepatol"},{"issue":"15","key":"11096_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC, Tsochatzis E, Petta S, Bugianesi E, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331(15):1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447","journal-title":"JAMA"},{"issue":"8","key":"11096_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de L\u00e9dinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u2013478. https:\/\/doi.org\/10.1038\/s41575-018-0014-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"11096_CR24","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/s2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714\u2013725. https:\/\/doi.org\/10.1016\/s2468-1253(23)00017-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"11096_CR25","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2018.01.005","volume":"154","author":"M Thiele","year":"2018","unstructured":"Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs fibrotest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology. 2018;154(5):1369\u20131379. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.005","journal-title":"Gastroenterology"},{"issue":"5","key":"11096_CR26","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006\u20131019. https:\/\/doi.org\/10.1136\/gutjnl-2021-324243","journal-title":"Gut"},{"issue":"17","key":"11096_CR27","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","volume":"393","author":"L Castera","year":"2025","unstructured":"Castera L, Rinella ME, Tsochatzis EA. Noninvasive assessment of liver fibrosis. N Engl J Med. 2025;393(17):1715\u20131729. https:\/\/doi.org\/10.1056\/NEJMra2403308","journal-title":"N Engl J Med"},{"issue":"6","key":"11096_CR28","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1007\/s00330-023-10441-5","volume":"34","author":"S Duman","year":"2024","unstructured":"Duman S, Kuru D, Gumussoy M, Kiremitci S, Gokcan H, Ulas B, et al. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone. Eur Radiol. 2024;34(6):3882\u20133888. https:\/\/doi.org\/10.1007\/s00330-023-10441-5","journal-title":"Eur Radiol"},{"issue":"17","key":"11096_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1056\/NEJMcp2402121","volume":"392","author":"AH Krist","year":"2025","unstructured":"Krist AH, Bradley KA. Addressing alcohol use. N Engl J Med. 2025;392(17):1721\u20131731. https:\/\/doi.org\/10.1056\/NEJMcp2402121","journal-title":"N Engl J Med"},{"issue":"1","key":"11096_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","volume":"68","author":"W Fals-Stewart","year":"2000","unstructured":"Fals-Stewart W, O\u2019Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol. 2000;68(1):134\u2013144. https:\/\/doi.org\/10.1037\/0022-006X.68.1.134","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"11096_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s2468-1253(24)00380-7","volume":"10","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz LA, K\u00f6nig D, Weber S, Ayares G, Fuentealba JM, V\u00e1zquez V, et al. Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. Lancet Gastroenterol Hepatol. 2025;10(5):475\u2013490. https:\/\/doi.org\/10.1016\/s2468-1253(24)00380-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"11096_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s2468-1253(24)00427-8","volume":"10","author":"A Krag","year":"2025","unstructured":"Krag A, Torp N, Younossi ZM, Israelsen M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol Hepatol. 2025;10(4):282\u2013284. https:\/\/doi.org\/10.1016\/s2468-1253(24)00427-8","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"11096_CR33","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s40429-021-00402-7","volume":"8","author":"JC Harris","year":"2021","unstructured":"Harris JC, Leggio L, Farokhnia M. Blood biomarkers of alcohol use: a scoping review. Curr Addict Rep. 2021;8(4):500\u2013508. https:\/\/doi.org\/10.1007\/s40429-021-00402-7","journal-title":"Curr Addict Rep"},{"issue":"6","key":"11096_CR34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/acer.14611","volume":"45","author":"JA Hahn","year":"2021","unstructured":"Hahn JA, Murnane PM, Vittinghoff E, Muyindike WR, Emenyonu NI, Fatch R, et al. Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta-analysis. Alcohol Clin Exp Res. 2021;45(6):1166\u20131187. https:\/\/doi.org\/10.1111\/acer.14611","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"11096_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70489","volume":"46","author":"ED Rady","year":"2026","unstructured":"Rady ED, Cotter TG. Integrating phosphatidylethanol to enhance alcohol quantification in steatotic liver disease and clinical trials. Liver Int. 2026;46(1): e70489. https:\/\/doi.org\/10.1111\/liv.70489","journal-title":"Liver Int"},{"issue":"1","key":"11096_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101200","volume":"7","author":"ED Hansen","year":"2025","unstructured":"Hansen ED, Torp N, Johansen S, Hansen JK, Bergmann ML, Hansen CD, et al. Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake. JHEP Rep. 2025;7(1): 101200. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101200","journal-title":"JHEP Rep"},{"issue":"6","key":"11096_CR37","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1053\/j.gastro.2025.07.007","volume":"169","author":"R Loomba","year":"2025","unstructured":"Loomba R, Hagstr\u00f6m H, D\u00edaz LA. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard? Gastroenterology. 2025;169(6):1103\u20131107. https:\/\/doi.org\/10.1053\/j.gastro.2025.07.007","journal-title":"Gastroenterology"},{"issue":"3","key":"11096_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K, et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024;9(3):218\u2013228. https:\/\/doi.org\/10.1016\/s2468-1253(23)00443-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"11096_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101433","volume":"7","author":"BTK Vanlerberghe","year":"2025","unstructured":"Vanlerberghe BTK, Dumitrascu C, den Eede NV, Neels H, van Malenstein H, Gevers TJG, et al. Phosphatidylethanol and ethyl glucuronide to categorize alcohol consumption in alcohol-related cirrhosis. JHEP Rep. 2025;7(8): 101433. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101433","journal-title":"JHEP Rep"},{"issue":"4","key":"11096_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/alcalc\/agy031","volume":"53","author":"ID Munsterman","year":"2018","unstructured":"Munsterman ID, Groefsema MM, Weijers G, Klein WM, Swinkels DW, Drenth JPH, et al. Biochemical effects on the liver of 1 month of alcohol abstinence in moderate alcohol consumers. Alcohol Alcohol. 2018;53(4):435\u2013438. https:\/\/doi.org\/10.1093\/alcalc\/agy031","journal-title":"Alcohol Alcohol"},{"key":"11096_CR41","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijpsycho.2022.05.015","volume":"177","author":"A Mart\u00ednez-Maldonado","year":"2022","unstructured":"Mart\u00ednez-Maldonado A, Rubio G, Sion A, Jurado-Barba R. Brain oscillatory functioning after long-term alcohol abstinence. Int J Psychophysiol. 2022;177:240\u2013248. https:\/\/doi.org\/10.1016\/j.ijpsycho.2022.05.015","journal-title":"Int J Psychophysiol"},{"issue":"6","key":"11096_CR42","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, Calleja JL, Vilar-Gomez E, Iruzubieta P, Rodr\u00edguez-Duque JC, Del Barrio M, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2024;81(6):930\u2013940. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.036","journal-title":"J Hepatol"},{"issue":"1","key":"11096_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-statistics-040720-032818","volume":"8","author":"PF Thall","year":"2021","unstructured":"Thall PF. Adaptive enrichment designs in clinical trials. Annu Rev Stat Appl. 2021;8(1):393\u2013411. https:\/\/doi.org\/10.1146\/annurev-statistics-040720-032818","journal-title":"Annu Rev Stat Appl"},{"issue":"3","key":"11096_CR44","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s13142-014-0265-0","volume":"4","author":"D Almirall","year":"2014","unstructured":"Almirall D, Nahum-Shani I, Sherwood NE, Murphy SA. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research. Transl Behav Med. 2014;4(3):260\u2013274. https:\/\/doi.org\/10.1007\/s13142-014-0265-0","journal-title":"Transl Behav Med"},{"issue":"9","key":"11096_CR45","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","volume":"21","author":"BP Lee","year":"2024","unstructured":"Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nat Rev Gastroenterol Hepatol. 2024;21(9):626\u2013645. https:\/\/doi.org\/10.1038\/s41575-024-00936-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"11096_CR46","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1097\/01.Alc.0000093743.03049.80","volume":"27","author":"CS Lieber","year":"2003","unstructured":"Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765\u20131772. https:\/\/doi.org\/10.1097\/01.Alc.0000093743.03049.80","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"11096_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-79428-6","volume":"14","author":"HA Lee","year":"2024","unstructured":"Lee HA, Lee HA, Kim HY. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms. Sci Rep. 2024;14(1): 28951. https:\/\/doi.org\/10.1038\/s41598-024-79428-6","journal-title":"Sci Rep"},{"issue":"10","key":"11096_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101165","volume":"6","author":"E Avitabile","year":"2024","unstructured":"Avitabile E, Gratac\u00f3s-Gin\u00e8s J, P\u00e9rez-Guasch M, Bel\u00e9n Rubio A, Herms Q, Cervera M, et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep. 2024;6(10): 101165. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101165","journal-title":"JHEP Rep"},{"issue":"2","key":"11096_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-025-03870-z","volume":"65","author":"UM Stern","year":"2026","unstructured":"Stern UM, Wagenpfeil G, Weber SN, Alqahtani SA, Michel M, Schattenberg JM. The impact of dietary interventions on liver health biomarkers in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic literature review and meta-analysis of randomized controlled trials. Eur J Nutr. 2026;65(2): 58. https:\/\/doi.org\/10.1007\/s00394-025-03870-z","journal-title":"Eur J Nutr"},{"issue":"4","key":"11096_CR50","doi-asserted-by":"publisher","DOI":"10.20517\/mtod.2025.61","volume":"5","author":"P Acu\u00f1a","year":"2025","unstructured":"Acu\u00f1a P, Albhaisi O, Idalsoaga F, Alkhouri N, Noureddin M, D\u00edaz LA, et al. Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review. Metab Target Organ Damage. 2025;5(4): 52","journal-title":"Metab Target Organ Damage"},{"issue":"6","key":"11096_CR51","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","volume":"16","author":"SP Ivy","year":"2010","unstructured":"Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1726\u20131736. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1961","journal-title":"Clin Cancer Res"},{"issue":"4","key":"11096_CR52","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643\u201354 e1-9. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"11096_CR53","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"6","key":"11096_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"1","key":"11096_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14010040","volume":"14","author":"A Lonardo","year":"2024","unstructured":"Lonardo A, Ballestri S, Mantovani A, Targher G, Bril F. Endpoints in NASH clinical trials: are we blind in one eye? Metabolites. 2024;14(1): 40. https:\/\/doi.org\/10.3390\/metabo14010040","journal-title":"Metabolites"},{"issue":"5","key":"11096_CR56","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","volume":"76","author":"J Boursier","year":"2022","unstructured":"Boursier J, Hagstrom H, Ekstedt M, Moreau C, Bonacci M, Cure S, et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol. 2022;76(5):1013\u20131020. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.031","journal-title":"J Hepatol"},{"issue":"4","key":"11096_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"issue":"10504","key":"11096_CR58","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","volume":"406","author":"M Noureddin","year":"2025","unstructured":"Noureddin M, Frias JP, Neff GW, Lucas KJ, Behling C, Bedossa P, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet. 2025;406(10504):719\u2013730. https:\/\/doi.org\/10.1016\/S0140-6736(25)01073-6","journal-title":"Lancet"},{"issue":"1","key":"11096_CR59","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/hep.32594","volume":"77","author":"T Gidener","year":"2023","unstructured":"Gidener T, Dierkhising RA, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023;77(1):268\u2013274. https:\/\/doi.org\/10.1002\/hep.32594","journal-title":"Hepatology"},{"issue":"11","key":"11096_CR60","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(11):2274\u201383 e5. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.061","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"11096_CR61","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.cgh.2022.08.036","volume":"21","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Sharpton SR, Amangurbanova M, Tamaki N, Sirlin CB, Loomba R, et al. Clinical utility of combined MRI-PDFF and ALT response in predicting histologic response in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(10):2682\u20132685. https:\/\/doi.org\/10.1016\/j.cgh.2022.08.036","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"11096_CR62","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/hep.30314","volume":"69","author":"JG Abraldes","year":"2019","unstructured":"Abraldes JG, Trebicka J, Chalasani N, D\u2019Amico G, Rockey DC, Shah VH, et al. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension. Hepatology. 2019;69(3):1287\u20131299. https:\/\/doi.org\/10.1002\/hep.30314","journal-title":"Hepatology"},{"issue":"1","key":"11096_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jhep.2020.08.009","volume":"74","author":"E Sola","year":"2021","unstructured":"Sola E, Pose E, Campion D, Piano S, Roux O, Simon-Talero M, et al. Endpoints and design of clinical trials in patients with decompensated cirrhosis: position paper of the LiverHope Consortium. J Hepatol. 2021;74(1):200\u2013219. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.009","journal-title":"J Hepatol"},{"issue":"1","key":"11096_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01478-25","volume":"70","author":"T Hamasaki","year":"2026","unstructured":"Hamasaki T, He Y, Wu Q, Howard-Anderson J, Boucher HW, Doernberg SB, et al. A patient-centric paradigm and tool for clinical research: the DOOR is open. Antimicrob Agents Chemother. 2026;70(1): e0147825. https:\/\/doi.org\/10.1128\/aac.01478-25","journal-title":"Antimicrob Agents Chemother"},{"issue":"46","key":"11096_CR65","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1093\/eurheartj\/ehaa665","volume":"41","author":"B Redfors","year":"2020","unstructured":"Redfors B, Gregson J, Crowley A, McAndrew T, Ben-Yehuda O, Stone GW, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J. 2020;41(46):4391\u20134399. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa665","journal-title":"Eur Heart J"},{"issue":"4","key":"11096_CR66","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2025.04.018","volume":"83","author":"M Tonon","year":"2025","unstructured":"Tonon M, Gagliardi R, Pompili E, Barone A, Zaccherini G, Zilio G, et al. Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease. J Hepatol. 2025;83(4):888\u2013898. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.018","journal-title":"J Hepatol"},{"issue":"3","key":"11096_CR67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12072-021-10155-0","volume":"15","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang A, Zhou T, Wang M, Chen Y, Zhou T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial. Hepatol Int. 2021;15(3):741\u2013752. https:\/\/doi.org\/10.1007\/s12072-021-10155-0","journal-title":"Hepatol Int"},{"issue":"3","key":"11096_CR68","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"LS Belli","year":"2016","unstructured":"Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524\u2013531. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.010","journal-title":"J Hepatol"},{"issue":"10","key":"11096_CR69","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.14309\/ajg.0000000000001883","volume":"117","author":"T Jamali","year":"2022","unstructured":"Jamali T, Raasikh T, Bustamante G, Sisson A, Tandon P, Duarte-Rojo A, et al. Outcomes of exercise interventions in patients with advanced liver disease: a systematic review of randomized clinical trials. Am J Gastroenterol. 2022;117(10):1614\u20131620. https:\/\/doi.org\/10.14309\/ajg.0000000000001883","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"11096_CR70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40290-024-00526-x","volume":"38","author":"MA Belnap","year":"2024","unstructured":"Belnap MA, McManus KR, Grodin EN, Ray LA. Endpoints for pharmacotherapy trials for alcohol use disorder. Pharmaceut Med. 2024;38(4):291\u2013302. https:\/\/doi.org\/10.1007\/s40290-024-00526-x","journal-title":"Pharmaceut Med"},{"key":"11096_CR71","doi-asserted-by":"publisher","DOI":"10.20517\/mtod.2024.103","author":"AK Singal","year":"2025","unstructured":"Singal AK. Monitoring and treatment of alcohol use disorder: an integrated multidisciplinary model. Metab Target Organ Damage. 2025. https:\/\/doi.org\/10.20517\/mtod.2024.103","journal-title":"Metab Target Organ Damage"},{"key":"11096_CR72","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13108","author":"AK Singal","year":"2016","unstructured":"Singal AK, Kodali S, Vucovich LA, Darley-Usmar V, Schiano TD. Diagnosis and treatment of alcoholic hepatitis: a systematic review. Alcohol Clin Exp Res. 2016. https:\/\/doi.org\/10.1111\/acer.13108","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"11096_CR73","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S2468-1253(25)00188-8","volume":"10","author":"C Celsa","year":"2025","unstructured":"Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025;10(11):998\u20131012. https:\/\/doi.org\/10.1016\/S2468-1253(25)00188-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11096_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/nu12103213","author":"YE Kunduraci","year":"2020","unstructured":"Kunduraci YE, Ozbek H. Does the energy restriction intermittent fasting diet alleviate metabolic syndrome biomarkers? A randomized controlled trial. Nutrients. 2020. https:\/\/doi.org\/10.3390\/nu12103213","journal-title":"Nutrients"},{"issue":"5","key":"11096_CR75","doi-asserted-by":"publisher","first-page":"950","DOI":"10.14309\/ajg.0000000000003379","volume":"120","author":"AK Singal","year":"2025","unstructured":"Singal AK, Wong RJ, Dasarathy S, Abdelmalek MF, Neuschwander-Tetri BA, Limketkai BN, et al. ACG clinical guideline: malnutrition and nutritional recommendations in liver disease. Am J Gastroenterol. 2025;120(5):950\u2013972. https:\/\/doi.org\/10.14309\/ajg.0000000000003379","journal-title":"Am J Gastroenterol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11096-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:41:05Z","timestamp":1787758865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11096-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11096"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11096-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AKS serves as a consultant on the SBIR grant for Pleiogenic pharma; served as DSMB member for phase-2b DUR-928 trial for Durect pharma; serves on advisory board for Orphalan, Disc Medicine, Ipsen, and Madrigal; Speaks and writes for Medscape, CLD Foundation, Expert Perspectives, Gastro Endo News, Dynamed, Medical Education Speakers Network, Up-to-Date, Madrigal Pharma, and Practice Point.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human subjects.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human\/animal subjects.","order":3,"name":"Ethics","label":"Human\/animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}